Skip to main content

Advertisement

SpringerLink
Log in

Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer

  • Original Article
  • Published:
International Journal of Clinical Oncology Aims and scope Submit manuscript

Abstract

Objectives

This study was conducted to evaluate the efficacy and safety of S-1 in patients with advanced non-small-cell lung cancer (NSCLC), receiving two or more prior chemotherapy regimens.

Methods

S-1 was administered orally for 14 consecutive days, followed by a 7-day rest period. This treatment course was repeated until disease progression or intolerable toxicity occurred.

Results

From 2010 to 2012, 45 patients were enrolled in this study. Of the 45 patients, 4 patients [8.9 %, 95 % confidence interval (CI) 0.6–17.2 %] exhibited a partial response and 24 patients (53.3 %) exhibited stable disease. The disease control rate was 62.2 % (95 % CI 48.1–76.4 %). Median progression-free survival was 71 days, and median survival time was 205 days. Four patients had grade 3 hematological toxicities, but toxicities of grade 4 were not observed in this study.

Conclusion

Although S-1 monotherapy as third-line treatment or beyond was well tolerated, the response rate for this regimen did not demonstrate sufficient activity for patients with advanced NSCLC.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Jemal A, Siegal R, Ward E et al (2009) Cancer statistics, 2009. CA Cancer J Clin 59:225–249

    Article  PubMed  Google Scholar 

  2. Shiroyama T, Kijima T, Komuta K et al (2012) Phase II tailored S-1 regimen study of first-line chemotherapy in elderly patients with advanced and recurrent non-small cell lung cancer. Cancer Chemother Pharmacol 70:783–789

    Article  CAS  PubMed  Google Scholar 

  3. Morgensztern D, Ng SH, Gao F et al (2010) Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey. J Thorac Oncol 5:29–33

    Article  PubMed  Google Scholar 

  4. Schiller JH, Harrington D, Belani CP, Eastern Cooperative Oncology Group et al (2002) Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92–98

    Article  CAS  PubMed  Google Scholar 

  5. Ohe Y, Ohashi Y, Kubota K et al (2007) Randomized phase III study of cisplatin plus irinotecan versus carboplatin plus paclitaxel, cisplatin plus gemcitabine, and cisplatin plus vinorelbine for advanced non-small-cell lung cancer: Four-Arm Cooperative Study in Japan. Ann Oncol 18:317–323

    Article  CAS  PubMed  Google Scholar 

  6. Shepherd FA, Dancey J, Ramlau R et al (2000) Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095–2103

    CAS  PubMed  Google Scholar 

  7. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, National Cancer Institute of Canada Clinical Trials Group et al (2005) Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123–132

    Article  CAS  PubMed  Google Scholar 

  8. Hanna N, Shepherd FA, Fossella FV et al (2004) Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy. J Clin Oncol 22:1589–1597

    Article  CAS  PubMed  Google Scholar 

  9. Matsubara N, Maemondo M, Inoue A et al (2013) A phase II study of irinotecan as a third- or fourth-line treatment for advanced non-small cell lung cancer: NJLCG0703. Respir Investig 51:28–34

    Article  PubMed  Google Scholar 

  10. Harada T, Oizumi S, Ito K, Hokkaido Lung Cancer Clinical Study Group et al (2013) A phase II study of amrubicin as a third-line or fourth-line chemotherapy for patients with non-small cell lung cancer: Hokkaido lung cancer clinical study group trial (HOT) 0901. Oncologist 18:439–445

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  11. Shirasaka T, Nakano K, Takechi T et al (1996) Antitumor activity of 1 M tegafur-0.4 M 5-chloro-2,4-dihydroxypyridine-1 M potassium oxonate (S-1) against human colon carcinoma orthotopically implanted into nude rats. Cancer Res 56:2602–2606

    CAS  PubMed  Google Scholar 

  12. Takechi T, Nakano K, Uchida J et al (1997) Antitumor activity and low intestinal toxicity of S-1, a new formulation of oral tegafur, in experimental tumor models in rats. Cancer Chemother Pharmacol 39:205–211

    Article  CAS  PubMed  Google Scholar 

  13. Govindan R, Morgensztern D, Kommor MD et al (2011) Phase II trial of S-1 as second-line therapy in patients with advanced non-small cell lung cancer. J Thorac Oncol 6:790–795

    Article  PubMed  Google Scholar 

  14. Hashizume T, Nakada Y (2009) S-1 monotherapy in patients with pretreated advanced non-small cell lung cancer. Gan To Kagaku Ryoho 36:963–967

    PubMed  Google Scholar 

  15. Shiroyama T, Komuta K, Imamura F et al (2011) Phase II study of S-1 monotherapy in platinum-refractory, advanced non-small cell lung cancer. Lung Cancer 74:85–88

    PubMed  Google Scholar 

  16. Totani Y, Saito Y, Hayashi M et al (2009) A phase II study of S-1 monotherapy as second-line treatment for advanced non-small cell lung cancer. Cancer Chemother Pharmacol 64:1181–1185

    Article  CAS  PubMed  Google Scholar 

  17. Wada M, Yamamoto M, Ryuge S et al (2012) Phase II study of S-1 monotherapy in patients with previously treated, advanced non-small-cell lung cancer. Cancer Chemother Pharmacol 69:1005–1011

    Article  CAS  PubMed  Google Scholar 

  18. Takakuwa O, Oguri T, Maeno K et al (2010) Efficacy of S-1 monotherapy for non-small cell lung cancer after the failure of two or more prior chemotherapy regimens. Oncol Lett 1:147–150

    CAS  PubMed Central  PubMed  Google Scholar 

  19. Ono A, Naito T, Murakami H et al (2010) Evaluation of S-1 as third- or further-line chemotherapy in advanced non-small-cell lung cancer. Int J Clin Oncol 15:161–165

    Article  CAS  PubMed  Google Scholar 

  20. Massarelli E, Andre F, Liu DD et al (2003) A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:55–61

    Article  CAS  PubMed  Google Scholar 

  21. Yoshioka H, Okamoto I, Morita S et al (2013) Efficacy and safety analysis according to histology for S-1 in combination with carboplatin as first-line chemotherapy in patients with advanced non-small-cell lung cancer: updated results of the West Japan Oncology Group LETS study. Ann Oncol 24:1326–1331

    Article  CAS  PubMed  Google Scholar 

  22. Kawahara M, Furuse K, Segawa Y, S-1 Cooperative Study Group (Lung Cancer Working Group) et al (2001) Phase II study of S-1, a novel oral fluorouracil, in advanced non-small-cell lung cancer. Br J Cancer 85:939–943

    Article  CAS  PubMed Central  PubMed  Google Scholar 

  23. Furuse K, Kawahara M, Hasegawa K, S-1 Cooperative Study Group (Lung Cancer Working Group) et al (2001) Early phase II study of S-1, a new oral fluoropyrimidine, for advanced non-small-cell lung cancer. Int J Clin Oncol 6:236–241

    Article  CAS  PubMed  Google Scholar 

Download references

Conflict of interest

The authors declare that they have no conflict of interest.

Author information

Authors and Affiliations

  1. Department of Cardiology, Pulmonology, Hypertension and Nephrology, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime, 791-0295, Japan

    Seigo Miyoshi, Ryoji Ito, Hitoshi Katayama, Hironobu Hamada, Takafumi Okura & Jitsuo Higaki

  2. Department of Respiratory Medicine, Uwajima City Hospital, Goten, Uwajima, Ehime, 798-0061, Japan

    Hitoshi Katayama

  3. Department of Pulmonary Medicine, National Hospital Organization Matsue Medical Center, Agenogi, Matsue, Shimane, 690-8556, Japan

    Toru Kadowaki & Shuichi Yano

  4. Department of Internal Medicine, NHO Ehime Medical Center, Yokogawara, Toon, Ehime, 791-0281, Japan

    Akira Watanabe & Masahiro Abe

  5. Department of Physical Analysis and Therapeutic Sciences, Graduate School of Biomedical and Health Sciences, Hiroshima University, Kasumi, Minami-ku, Hiroshima, 734-8553, Japan

    Hironobu Hamada

Authors
  1. Seigo Miyoshi
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryoji Ito
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Hitoshi Katayama
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Toru Kadowaki
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Shuichi Yano
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Akira Watanabe
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Masahiro Abe
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Hironobu Hamada
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. Takafumi Okura
    View author publications

    You can also search for this author in PubMed Google Scholar

  10. Jitsuo Higaki
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ryoji Ito.

About this article

Cite this article

Miyoshi, S., Ito, R., Katayama, H. et al. Phase II trial of S-1 as third-line or further chemotherapy in patients with advanced non-small-cell lung cancer. Int J Clin Oncol 19, 1005–1010 (2014). https://doi.org/10.1007/s10147-014-0663-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10147-014-0663-9

Keywords

Search

Navigation